Site icon OncologyTube

Dr Hans Hammers discusses highlights from the Thirteenth International Kidney Cancer Symposium, including unmet needs of patients with non-clear cell renal cell carcinoma (nccRCC)

Dr Hans Hammers (Johns Hopkins, MD) discusses highlights from the Thirteenth International Kidney Cancer Symposium. Immunotherapies have received significant interest: immune checkpoint inhibitors have the potential to durably control disease. Although significant progress has been made in the clear cell renal cell carcinoma (RCC) subtype, research in therapies for non-clear cell RCC (nccRCC) has been relatively neglected.

Exit mobile version